01 How it works
PT-141 activates melanocortin receptors (mainly MC4R) in the brain, which are involved in sexual motivation. That is a different route from drugs like sildenafil, which work on blood flow — so it addresses desire rather than mechanics.
02 Common uses
03 Run profile
PT-141 is not run on a schedule. It is taken as needed, ahead of time, and not more than once in 24 hours. Many people start below the usual amount to see how they react.
The profile shows the shape. Ask for the numbers for your vial, your goal and your timeline.
04 What to watch for
Nausea is the most common effect, along with flushing and headache. It can briefly raise blood pressure, so it is not for anyone with uncontrolled high blood pressure or heart disease. Darkening of the skin has been reported with frequent use.
05 Evidence & status
Approved (as Vyleesi®)Studied in phase 3 trials (RECONNECT) for low desire in premenopausal women, which led to its approval.
FDA-approved as Vyleesi® for low sexual desire in premenopausal women. Other uses are off-label.
Sources
- VYLEESI- bremelanotide injection (prescribing information)DailyMed, U.S. National Library of Medicine, 2024 · Prescribing information
- VYLEESI (bremelanotide injection), for subcutaneous use - initial FDA-approved labelU.S. Food and Drug Administration (Drugs@FDA), 2019 · Prescribing information
- NDA 210557 approval letter (Vyleesi)U.S. Food and Drug Administration (Drugs@FDA), 2019 · Regulator document
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsObstetrics & Gynecology, 2019 · Clinical trial
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderObstetrics & Gynecology, 2019 · Clinical trial
- The Prohibited ListWorld Anti-Doping Agency, 2026 · Regulator document
Status and sources last checked November 3, 2026. Something out of date? Tell us.
06 How long until it works
PT-141 is taken as needed, not built up, so the question is hours, not weeks. The Vyleesi label says to inject at least 45 minutes before anticipated sexual activity, and the effect window is several hours. The RECONNECT phase 3 trials, which ran 24 weeks in premenopausal women with low desire, measured the change in desire and distress over the course of use; the gains were modest but statistically clear, and side effects were front-loaded in the first doses.
What the label limits: no more than one dose in 24 hours, and no more than eight doses a month. The page’s “start below the usual amount” note is about the nausea, which is the main reason people stop.
07 PT-141 vs sildenafil-type drugs
They do different jobs. Sildenafil and its relatives act on blood flow and do nothing for desire; PT-141 acts on melanocortin receptors in the brain and does nothing for blood flow. That is why the page lists “when blood-flow medications have not helped” as a use: for low desire, the mechanics drugs were never the right tool.
The evidence base is also different in kind. Sildenafil has decades of data in men; PT-141’s approval trials were in premenopausal women, and its label says it is not indicated for men or for postmenopausal women. Use in men is off-label and rests on earlier, smaller studies that did not lead to approval.
08 Stacking
PT-141 is not stacked in the usual sense; it is taken on its own, as needed. The label interaction that matters is with blood pressure: it causes a brief rise after each dose, so it is not for anyone with uncontrolled hypertension or heart disease, and it can slow the absorption of some oral medicines taken around the same time, which the label flags for drugs with a narrow margin.
09 Where it stands legally
PT-141 is FDA-approved as Vyleesi (bremelanotide) for acquired, generalised hypoactive sexual desire disorder in premenopausal women, approved in June 2019. Use in men, and in postmenopausal women, is off-label. Because it is the active ingredient of an approved medicine, pharmacies can compound it within the usual 503A rules for patient-specific prescriptions; it is not among the six peptides in the October 2026 HHS policy and is not affected by it.
In sport, bremelanotide is not named on WADA’s Prohibited List and is an approved medicine, so the S0 “non-approved” category does not apply; athletes should still check with their anti-doping body.
10 FAQ
How far ahead is it taken?
Usually some time before activity — ask for the details for your situation.
Does it work for men?
It is approved for women, but it acts on the brain rather than on blood flow and is used by men too.
How do I handle the nausea?
Starting low is the usual approach; ask for specifics.
Does PT-141 work for men?
It is not approved for men, and the label says so. Earlier studies in men did not lead to approval. Use in men is off-label, and the blood-pressure caution applies just as much.
How many times a month can I take it?
The label limit is one dose in 24 hours and no more than eight doses a month. Skin darkening was more common in trials in people who exceeded eight doses a month.
What is the skin darkening about?
PT-141 is a melanocortin agonist, the same receptor family that drives pigmentation. Patches of darker skin on the face, gums or breasts were reported in about 1% of trial participants and more often with frequent dosing; they may not fully fade.
Is PT-141 banned in sport?
It is not named on WADA’s list and it is an approved medicine. Check with your anti-doping body if you are tested.
Educational information only — not medical advice. The Daily Stack does not sell or supply any products. Talk to a licensed healthcare professional about your own health decisions.